Envista (NYSE:NVST – Get Free Report) had its price objective upped by investment analysts at Evercore ISI from $18.00 to $23.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Evercore ISI’s target price indicates a potential upside of 22.08% from the company’s current price.
Other research analysts have also recently issued reports about the stock. Piper Sandler lowered their price target on shares of Envista from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, July 30th. Robert W. Baird lowered their target price on Envista from $19.00 to $17.00 and set a “neutral” rating on the stock in a research note on Monday, July 22nd. JPMorgan Chase & Co. downgraded Envista from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $23.00 to $16.00 in a research note on Thursday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of Envista in a report on Thursday, August 8th. Finally, Bank of America reduced their target price on shares of Envista from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $19.59.
View Our Latest Analysis on Envista
Envista Trading Down 1.2 %
Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.16). The business had revenue of $633.10 million during the quarter, compared to analyst estimates of $646.88 million. Envista had a negative net margin of 52.25% and a positive return on equity of 4.86%. The business’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.43 earnings per share. Sell-side analysts forecast that Envista will post 0.69 earnings per share for the current year.
Insider Buying and Selling at Envista
In other news, CFO Eric D. Hammes purchased 24,532 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $16.33 per share, with a total value of $400,607.56. Following the acquisition, the chief financial officer now owns 24,532 shares in the company, valued at approximately $400,607.56. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.30% of the company’s stock.
Hedge Funds Weigh In On Envista
Institutional investors have recently modified their holdings of the business. Alberta Investment Management Corp raised its stake in Envista by 41.7% during the fourth quarter. Alberta Investment Management Corp now owns 294,417 shares of the company’s stock worth $7,084,000 after acquiring an additional 86,700 shares in the last quarter. Tweedy Browne Co LLC acquired a new position in Envista during the 1st quarter worth approximately $21,053,000. SG Americas Securities LLC lifted its stake in Envista by 3,271.2% in the 1st quarter. SG Americas Securities LLC now owns 144,522 shares of the company’s stock valued at $3,090,000 after purchasing an additional 140,235 shares during the last quarter. M&G Plc lifted its stake in Envista by 12.5% in the 2nd quarter. M&G Plc now owns 306,253 shares of the company’s stock valued at $5,206,000 after purchasing an additional 33,923 shares during the last quarter. Finally, Norges Bank acquired a new stake in Envista in the fourth quarter valued at approximately $42,874,000.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Recommended Stories
- Five stocks we like better than Envista
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Fintech Stocks With Good 2021 Prospects
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.